Biologics for chronic rhinosinusitis with nasal polyps: a real-world prospective cohort study - PubMed

3 hours ago

Biologics targeting type 2 inflammation (omalizumab, mepolizumab, dupilumab) were evaluated for severe chronic rhinosinusitis with nasal polyps (CRSwNP) in a real-world prospective study in Belgium.
After 6 months, improvements were seen across all biologics in nasal polyp score, olfactory function, patient-reported outcomes, and asthma control.
Good-to-excellent multidomain therapeutic response was achieved in 51% of patients, with dupilumab showing numerically larger improvements and higher treatment continuation rates (92%) compared to omalizumab (74%) and mepolizumab (81%).

Hasty Briefsbeta